This transaction marks the first major structural acquisition for Winncare following the entry of Siparex ETI as its majority shareholder earlier in 2021. By acquiring 100% of Pharmaouest Industries, Winncare has significantly strengthened its industrial capabilities and product portfolio in the high-stakes segment of pressure ulcer prevention. This horizontal integration allows Winncare to internalize advanced visco-elastic foam manufacturing technologies and leverage Pharmaouest's dual-site industrial setup in France and Tunisia to optimize its supply chain. The rationale for the merger is driven by the complementarity of the two groups, product lines and customer bases. The addition of Pharmaouest provides Winncare with a specialized R&D pipeline and a wider range of medical consumables specifically tailored for home care and elderly care institutions. Strategically, this acquisition acted as a catalyst for Winncare's growth, contributing to a 50% increase in the group's total revenue within the same fiscal year. The operation aligns with Winncare's long-term goal of becoming a diversified European leader in medical equipment by consolidating smaller, specialized manufacturers with high technical value. This deal also supports the group's commitment to a mission-driven corporate model, focusing on social impact and patient-centric innovation throughout the care journey.

Pharmaouest Industries is a prominent French manufacturer specializing in medical devices for pressure ulcer prevention and patient comfort, primarily serving the home care (MAD) and nursing home (EHPAD) sectors. The company possesses recognized technical expertise in the formulation and processing of visco-elastic foam, a critical component for high-performance therapeutic surfaces. Its business model is supported by a robust industrial footprint, featuring a specialized production plant in Ille-et-Vilaine and an additional industrial facility in Tunisia, providing the group with significant production capacity and cost-efficiency. Pharmaouest,s value proposition centers on its ability to deliver innovative, high-quality medical foam products that meet the specific clinical requirements of long-term care facilities. The company,s strategy focuses on continuous product development to enhance the patient care pathway, ensuring safety and skin integrity for individuals with reduced mobility. By maintaining control over its manufacturing process, Pharmaouest ensures high responsiveness to the evolving needs of healthcare providers and institutional distributors across the French and international markets.